Clinical Trials
Peg-Intron maintenance study in patients coinfected with hepatitis C and HIV initiated
Published in AIDS Weekly, February 6th, 2006
Schering-Plough announced that it is initiating a large multinational clinical trial to evaluate the use of low-dose Peg-Intron (peginterferon alfa-2b) maintenance monotherapy in preventing or delaying hepatitis C disease progression and thus potentially reducing the occurrence of clinical events such as liver transplantation, liver cancer and death in cirrhotic patients with hepatitis C who are coinfected with HIV.
Known as the ENDURE study, the trial is targeted to enroll 448 patients at approximately 80 sites worldwide, including centers in the United States, Europe and Canada.
Approximately one third of HIV patients, or about 10 million people...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
Source: AIDS Weekly (2006-02-06)
More Articles from AIDS Weekly
- HIV/AIDS Drug Development
Bifunctional HIV-1 inhibitors simultaneously block CD4 and CCR5 receptors - HIV/AIDS Drug Interaction
Ritonavir increases systemic exposure of prednisolone - HIV/AIDS Drug Resistance
Recent HIV-1 seroconverters more likely to have transmitted drug resistance - HIV/AIDS Epidemiology
Frequency of HIV/AIDS protective SDF1-3'A gene high among blood donors in Crete - HIV/AIDS HAART
HIV RNA sustained below 20 copies/mL may prevent 184V mutation in CD4 cell DNA - Allergy & Immunology
Cytomegalovirus infection inhibits immune responses generated against P. carinii - More from this issue of AIDS Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
